Grace Therapeutics, Inc. GRCE
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
13.53
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2026 | — | -$7.8M | — | — | $63.9M |
| 2025 | — | -$9.6M | — | — | $66.6M |
| 2024 | — | -$12.9M | — | — | $61.7M |
| 2023 | — | -$42.4M | — | — | $68.0M |
| 2022 | $100.0M | -$9.8M | — | — | $108.3M |
| 2021 | $196,000 | -$19.7M | — | — | $55.7M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 13.53 (safe)
- Working capital / assets 0.229
- Retained earnings / assets -3.428
- EBIT / assets -0.166
- Equity / liabilities 23.168
Source: SEC EDGAR filings · CIK 0001444192 · as of 2026-03-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.